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In December 2016, following the “Africa Regional Conference on Abortion: From Research to Policy,” a 
group of 20 global abortion researchers, representing nine different international organizations and 
universities, convened to discuss current and future research on medical abortion self-use 
(http://abortionresearchtopolicy.org). While recognizing the meaning of ‘self-use’ to be evolving, we 
considered women’s self-use of medical abortion as provision of drugs from pharmacies, drug sellers or 
through online services or other outlets, without a prescription from a clinician, followed by a woman’s 
self-management of the abortion process, including care-seeking for any complications.  
 
Research has not kept abreast of women’s self-use of medical abortion, leaving many gaps in the 
scientific literature regarding the ideal conditions for safe and effective use. Therefore, our main 
objectives were to assess the research gaps highlighted during the conference, identify specific 
challenges to conducting research on medical abortion self-use, and to share promising research 
methodologies to advance this research. Although there are overlaps with the recommended  and well-
researched practice of women’s self-management of the abortion process at home after receiving 
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medical abortion medicines, screening and information from a clinician [1], our intent was focused on 
the emerging practice of self-use.  
 
The challenges laid out in this document—a list of identified research gaps and methodologic 
considerations in addressing them-- are intended to inform both ongoing and future research by the 
participants in this meeting; in sharing them, we hope to inform and validate not only our future work 
but also that of other researchers. 
 
Research gaps 
Women and adolescents are increasingly obtaining abortifacient medicines through informal routes 
including online services, pharmacies, hotlines, and drug sellers [2-6], though this trend and the current 
incidence has not been well documented. Such access is more common in settings where abortion 
services are either restricted or difficult to access [7]. Women themselves and different cadres of 
providers are developing and implementing innovative access strategies faster than they can be formally 
evaluated. We agreed that the role of research in this area would be to document this practice in 
restrictive and less-restricted settings with an aim to determine where interventions could increase 
safety, efficacy, and access to services, and to maximize meeting women’s preferences and comfort with 
medical abortion self-use. Restrictive settings are those where legal abortion indications are generally 
only for maternal health or life; however, settings which are nonrestrictive do not guarantee ready 
access to services and may pose similar difficulties for women to obtain safe abortion services. Thus we 
considered that these research questions are relevant for a range of legal settings. 
 
Research gaps can be summarized in three broad categories: women‘s preferences and experiences with 
self-use of medical abortion, the distribution and provision of medical abortion information and drugs, 
and clinical outcomes following self-use. For each of these three broad groups, we identify specific 
research questions varying in level of detail by the contexts they reflect.  
 
Questions related to women’s preferences and experiences using medical abortion 
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We know very little about women’s needs, wants and experiences with respect to medical abortion self-
use. Women are most satisfied when they receive the abortion method they prefer if they have choices 
between methods [8, 9], but in contexts where choice is limited, they are more likely to pursue other 
methods of abortion of varying degrees of safety, to terminate a pregnancy [10]. Understanding how 
medical abortion and particularly its self-use is perceived by women can facilitate interventions to shift 
care-seeking from less safe to safer methods. Quality research in this area would lead to the 
development and testing of interventions to address women’s perspectives and misconceptions around 
medical abortion and to mitigate barriers, within legal constraints, to preferred care.  
 Many questions relating to women’s preferences remain unanswered. As these preferences are better 
studied, they may also inform how to improve clinic-based or surgical services in restricted settings. 
These research gaps include: 
 Women’s awareness of potentially available safe abortion methods and in what way it 
influences their abortion decision making. 
  How, or if, women understand the efficacy and risks of different abortion methods, including 
traditional ones, and how it influences decision making. 
  Why women choose self-use and if they would do so even if all other options/technologies 
were available.  
 What would be an ideal self-use experience, from women’s point of view. 
 How women’s preferences are influenced by differences in experienced and internalized stigma 
in facility-based care versus self-use or some other combination. 
 
Generally, we know little about how women want to receive information on abortion, where, and from 
whom. We know even less about how literacy level and the quality of information received makes a 
difference to a woman’s experiences and outcomes with medical abortion, and whether this differs from 
other medicines accessed from a pharmacy. Research gaps that focus on the experiences of self-
screening and self-managing the abortion include:  
 Whether women are aware of the importance of estimating the gestational age of their 
pregnancy prior to medical abortion, and what support or tools they need to do so.  
 The extent to which self-use of medical abortion is happening in later gestations, particularly in 
the second trimester, and the resulting clinical outcomes. 
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 How women who are self-using manage side effects like pain and bleeding, what kind of support 
they prefer to receive during the process (hotlines, texting, smart phone applications or phone 
number of pharmacist/ chemist), and how they decide to seek medical assistance.  
 Whether specific counselling or information could assist women to manage their bleeding and 
products of conception, particularly those without access to a private toilet or absorbents. 
  How self-use of medical abortion affects subsequent use of post-abortion contraception, and 
how women would prefer to receive contraceptive information. 
 
Questions regarding the provision of medical abortion drugs and information  
Increasing availability of high-quality medical abortion drugs requires an understanding of how to best 
positively influence a range of distribution systems. Research in this area has the potential to inform 
policies around procurement and distribution to ensure quality products are available as almost all 
settings have some legal indications for abortion-related care. 
Research has assessed, in some settings, the role of pharmacists and other drug sellers in providing 
medical abortion, but little is known about how to improve the attitudes, knowledge and practices of 
pharmacists and drug sellers or about how to address the attitudes and comfort level of clinicians 
towards pharmacy provision without a prescription. 
Unanswered questions regarding the distribution or provision of mifepristone and misoprostol include:  
 Whether registration of mifepristone and misoprostol and/or inclusion on a country’s Essential 
Medicines List or by WHO prequalification affects drug availability and quality. 
 Through which outlets medical abortion pills are distributed, the quality of available drugs, and 
how sellers decide which products to stock and price.  
 What regimens are provided and whether they differ from the evidence-based regimens.  
 How can sellers ensure and promote the provision of quality medical abortion drugs and 
information, and how can purchasers know the quality of the drugs and whether this is different 
from other medicines.  
 How women determine the options for procuring drugs for medical abortion in their community 
or online. 
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Questions regarding clinical outcomes following self-use 
The safety and efficacy of mifepristone followed by misoprostol at gestational ages ≤10 weeks has been 
well-established when provided from a clinic setting with women self-managing the abortion process at 
home. Whether it differs among those obtaining the drugs without a clinician’s advice or prescription is 
not known: eligibility screening, provision of emergency services or provision of accurate information 
about how to take the pills and when to seek additional care may impact women’s experience and 
management of complications, as might the nature itself of clandestine self-use. If clinical outcomes and 
women’s experiences reflect or improve upon those obtained in facility-based care, then the policy 
implications would support changing the legal status of medical abortion drugs, developing 
interventions to promote the role of pharmacy workers, support and promote hotlines, and to develop 
understandable drug labelling.  
Investigating the outcomes of self-use should include assessments of the experiences, outcomes and 
proportions of patients who present for incomplete abortion care  and conversely, the outcomes and 
experiences of those women who do not present at facilities. Other research gaps include: 
 Whether there is a difference in the clinical outcomes depending on where women receive their 
medical abortion drugs, information and counselling (provider versus pharmacist or drug seller).  
 What is needed for women to self-screen eligibility for medical abortion. 
 Identifying objective measures of abortion-related complications to assist interpretation of 
women’s self-reported outcomes. 
 
Moving forward with research on self-use of medical abortion 
There are inherent methodological challenges in studying self-use of medical abortion, not the least of 
which is the reluctance of some governments, policy-makers and ethical review bodies to approve 
research in this area. We identified methodological challenges broadly related to recruitment, follow-up 
of research participants, resulting health outcomes, ethical concerns and securing ethical approval. 
Below, we describe the various challenges we identified and in some cases, methods which may address 
them.  
Recruiting research participants  
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Due to the clandestine nature of medical abortion self-use in most settings, an obvious challenge is 
recruitment of women who use medical abortion drugs in this manner, particularly if they are satisfied 
users. Unlike conducting traditional clinical studies, where care and study recruitment takes place in a 
health facility, recruitment of women using medical abortion completely outside of this formal setting 
requires different strategies. Pharmacies, drug sellers, community health workers or hotlines are all 
potential locations where recruitment could take place, but require that researchers understand where 
and how medical abortion drugs are available and accessed in the local setting.  
Advantages of working with drug sellers or community health workers who are distributing medical 
abortion drugs and/or information, include they are often known and trusted by women already using 
their services. Alternatively, recruiting through call centers, hotlines and internet sites of sale may be 
successful in specific settings where women commonly use these routes. Innovative community-based 
recruitment strategies are needed to understand some of the ways women self-use medical abortion 
drugs and their experiences. 
Researchers who have engaged with pharmacists to study self-use noted that pharmacists who are 
knowledgeable and motivated to participate in research may not be representative of the general 
population of pharmacists. Placing research assistants in the pharmacy to recruit women may be more 
efficient than relying on pharmacists or drug sellers to recruit; however, the cost and time implications 
may be prohibitive and there is a risk that their presence may discourage some people purchasing 
medicines. Research should be designed to mitigate this effect, as women may shift to less safe 
approaches rather than going to another pharmacy. 
An additional recruitment method is respondent driven sampling (RDS). RDS attempts to leverage a 
small non-random sample of point people (i.e. seeds) within social networks engaging in hidden or 
stigmatized behaviors to recruit others within their networks.  Through a systematized version of 
snowball sampling, and appropriately adjusting samples for potential selection bias, this approach can 
generate a prevalence estimate of the behavior of interest within the target population.  Like any 
statistical methodology, RDS has its limitations—specifically the accuracy of estimates can be influenced 
by recruitment dynamics and the distribution of the behavior within the network [11]—however, recent 
evidence suggests that rigorous formative research to identify appropriate initial seeds can improve the 
accuracy of estimates [12]. This recruitment method proved successful in the first RDS study of abortion 
where women were recruited with experience in abortion outside of the formal health system in Cape 
Town, South Africa [13]. 
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Following women who have self-used medical abortion drugs 
Another methodological issue for research of services taking place outside of clinics is tracking women 
who obtain abortifacients from pharmacies or drug sellers who are unlikely to return to these sites 
postabortion. Text messaging or a smart-phone application is one way to keep in contact with women as 
they self-manage their abortion and can provide a mechanism to inform the investigator of their clinical 
outcomes and experiences. An interactive application could also provide prompts for when to take a 
dose, reminders about expected bleeding, use of painkillers, tracking of bleeding, postabortion 
contraception, and to indicate available sources for health care services, if needed [14].  The provision of 
hotlines or phone numbers for women to call a knowledgeable person (e.g., trained counsellor, nurse-
midwife or pharmacist) for support and information may also provide a method for keeping in contact.  
The uptake of contraception postabortion likely differs among women who self-use medical abortion 
compared with those who receive facility-based care. Whether bundling the cost of both contraceptives 
and medical abortion drugs in a pharmacy setting increases contraceptive uptake, which methods 
women choose postabortion and their subsequent contraceptive continuation are all questions for 
research studies to better understand women’s preferences. 
Outcomes 
For self-use of medical abortion, the process of cramping, bleeding and pregnancy expulsion are 
necessarily self-reported. Objective measures to distinguish between complications and normal side 
effects are currently lacking or difficult to implement, even with facility-based care. Assessment of final 
medical abortion outcomes should to rule out a continuing pregnancy within an appropriate time frame. 
Phone follow-up requires arranging convenient times to speak, avoiding revealing the study 
participation to other phone users, establishing trust on the phone so that she can share her 
experiences, ensuring privacy of the respondent so that she can answer the questions in a secure 
environment, and limiting the length of contact time to decrease any possible risk to the woman.  
Ethical concerns 
All research methodologies in this area of study must grapple with ethical issues pertaining to women’s 
self-use. Research settings should be one where there are some legal indications for abortion, and 
participants (women and drug sellers) would not risk prosecution from taking part in the study. In more 
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regulated settings, it may be necessary to use mystery clients or to avoid collecting identifying 
information on the women or drug providers. Seeking local ethical approval, as for any research, is best 
practice as ethics committees offer local cultural perspectives, may advise on the study approach of 
extra-legal behaviors which affect public health in their setting, are mindful of local public health 
priorities and encourages local buy-in for use of research findings.  
Age limits for assenting to a procedure or participating in research vary and might affect the design and 
participants who can be enrolled. In most settings, adolescents experience unintended pregnancy and 
seek induced abortion, including through self-use of medical abortion, but they can be particularly 
difficult to identify, recruit, enroll and follow-up. If unable to legally recruit women <18 years, one 
method to study adolescent experiences is to ask young adult women to recall their abortion 
experiences at these ages. In places where adolescents can consent to participate in research, 
recruitment through social media platforms may increase responsiveness, but may over-represent study 
participation to more urban, wealthier adolescents.  
 
Conclusion 
Although increasing numbers of women are seeking medical abortion outside of formal health systems, 
the global research agenda has yet to address the topic systematically. Self- use is likely expanding 
access to induced abortion, especially in legally restricted settings, and may reflect some women’s 
preferences; however, it may also reflect the only way for a woman faced with an unintended 
pregnancy to access a comparatively safe method of abortion, especially in more restricted settings or 
where formal health settings have fallen short.  
 
Establishing self-use of medical abortion as a legitimate or recommended approach calls for rigorous 
research and collaborative work. Cross-organizational research or joint proposals taking advantage of 
cross-discipline, cross-sector and multiple expertise would be beneficial, particularly because of the level 
of rigor required to address abortion-related stigma, misconceptions and the common biases held 
against women’s use of reproductive technologies.  
 
To advance an agenda of impactful research on the topic of self-use, we identify the following priority 
areas of study: 1) rigorously establishing the safety and efficacy of self-use compared with outcomes 
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following facility-based medical abortion care, 2) identifying how to best inform and support women in 
various settings in using the medicines safely and effectively, 3) documenting how to effectively 
facilitate the community distribution of high-quality medical abortion drugs and information and finally, 
4) determining the preferences of women in how they obtain induced abortion care to inform future 
interventions to meet their needs. Moving forward with this agenda has the possibility to transform 
women’s ability to access safe abortion for unintended pregnancy, ultimately decreasing the recourse to 
unsafe abortion and resulting morbidity and mortality. 
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